Hello! Welcome to the official website of Betta Pharmaceuticals!
Helpline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
Betta Pharmaceuticals received marketing approval of Icotinib indicating for first-line treatment of patients with advanced-stage NSCLC with EGFR mutation
Form: betta   Date: 2014-11-27

  On November 13th 2014, the Icotinib Hydrochloride Tablets developed and produced by Betta Pharmaceuticals Co., Ltd. was approved by China Food and Drug Administration to be used in first-line treatment of patients with advanced-stage NSCLC with EGFR mutation (Approval No.: 2014B02155). The approval of the indication will provide a new treatment option for many patients suffering from lung cancer in China.

  The approval of this new indication advanced icotinib’s application from the second, third-line treatment to the first-line and will aim to benefit more patients as early as possible, especially NSCLC patients with EGFR mutation. Not only does it meet the personalized treatment demands of more patients, it also provides suitable lung cancer patients with a more optimized treatment option.

 

Prev: The company’s patent won the gold medal of the 16th WIPO-SIPO Award for Chinese Outstanding Patented Invention & Industrial Design
Next: The Achievement of the “11th, 12th Five-Year Plan” New Drug Research and Development Major Program – The Academic Conference for the 3rd Anniversary of the release of Conmana was held in Hangzhou